Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Development and Characterization of Everolimus-Loaded Polycaprolactone Nanoparticles for Brain Tumor

Namdev Dhas – Associate Professor, Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences
Introduction:

Brain cancer treatment remains challenging due to the limited ability of most chemotherapeutic agents to cross the BBB. Everolimus, a potent mTOR inhibitor, has poor solubility and inadequate CNS penetration, which restricts its clinical efficacy. Nanoparticle-based delivery systems utilizing biodegradable polymers offer a promising approach to overcoming these limitations. This study aims to focus on the development of hyaluronic acid-conjugated, chitosan-coated, Everolimus-loaded polycaprolactone nanoparticles (HA@CS@EVR-PCL NPs) for targeted delivery (CD44 Receptors), pH-responsive release, and therapeutic performance.

Learning Objectives:

  • Formulate and optimize EVR-loaded PCL nanoparticles for targeted brain delivery.
  • Characterize the size, PDI, zeta potential, and drug loading of nanoparticles.
  • Evaluate drug release and validate RP-HPLC for accurate drug quantification.